VIRPAX PHARMACEUTICALS, INC. Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 8, 2023, Virpax Pharmaceuticals, Inc. (the "Company") received a letter (the "Notification Letter") from The Nasdaq Stock Market ("Nasdaq") stating that based on the filing of the Company's Form 10-Q for the period ended September 30, 2023 on December 7, 2023, Nasdaq has determined that the Company complies with the periodic filing requirement under Nasdaq Listing Rule 5250(c)(1).
The notification is separate from, and in addition to, the previously disclosed deficiency letter that the Company received from the Staff on April 10, 2023 with respect to the Company's failure to maintain a minimum closing bid price of $1.00 per share on any business day over a thirty consecutive business day period, as required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) which the Company has until April 8, 2024 to comply with.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Virpax Pharmaceuticals Inc. published this content on 13 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 December 2023 13:34:32 UTC.
